Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum

Gastric Cancer

Volumn 14, Issue 3, 2011, Pages 219-225

  Schoennemann, Katrine R ^a,b   Bjerregaard, Jon K ^a,b   Hansen, Tine P ^a   De Stricker, Karin ^a   Gjerstorff, Morten F ^c   Jensen, Helle A ^a   Vestermark, Lene W ^a   Pfeiffer, Per ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cetuximab; Irinotecan; KRAS protein; Second line therapy; Stomach neoplasm

Indexed keywords

ANTIEMETIC AGENT; ATROPINE; CETUXIMAB; CLEMASTINE; IRINOTECAN; ONDANSETRON; PANITUMUMAB; PLATINUM COMPLEX; PREDNISOLONE;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHOLINERGIC SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE ACTIVITY; DRUG CHOICE; DRUG INFUSION; DRUG TOLERABILITY; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FUNCTIONAL STATUS; GASTROESOPHAGEAL CANCER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE VOLVULUS; LEUKOPENIA; LUNG EMBOLISM; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SKIN TOXICITY; STOMACH CANCER; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; SALVAGE THERAPY; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80053916746     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-011-0031-7     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J, Pisani P, et al. Global cancer statistics 2002. CA Cancer J Clin. 2005;55:47-108.
2. Klint A, Engholm G, Storm HH, Tryggvadóttir L, Gislum M, Hakulinen T, et al. Trends in survival of patients diagnosed with cancer of the digestive organs in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol. 2010;49:578-607.
3. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of fluorouracil, epidoxorubicin, and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995; 71:587-91.
4. Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8:163-8. (Pubitemid 27112884)
5. Chau I, Norman A. R., Cunningham D., Oates J., Hawkinsv R., Iveson T, et al. Is there a differential chemotherapy effect in patients with locally advanced or metastatic oesophageal (O), oesophago-gastric junction (OGJ) and gastric (G) adenocarci-noma? A pooled analysis of four randomised controlled trials (RTCs). J Clin Oncol 2007 (abstract 75).
6. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36-46.
7. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluoro-uracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006; 24: 4991-7. (Pubitemid 46631401)
8. Thuss-Patience PC, Kretzschmar T, Deist T, Hinke A, Bichev D, Schumacher G, et al. Irinotecan versus best supportive care (BSC) as 2nd-line therapy in gastric cancer. A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol. 2009;27 (suppl) (abstract LBA 2400).
9. Leary A, Assersohn L, Cunningham D, Norman AR, Chong G, Brown G, et al. A phase II trial evaluating capecitabine and iri-notecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. Cancer Chemother Pharmacol 2009;64(3):455-62.
10. Chun JH, Kim HK, Lee JS, Choi JY, Lee HG, Yoon SM, et al. Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol. 2004;34:8-13. (Pubitemid 43118052)
11. Ajani JA, Baker J, Pisters PW, Ho L, Feing B, Mansfiels PF. Irinotecan plus cisplatin in advanced gastric or gastro esophageal junction carcinoma. Oncology (Williston Park). 2001;15:52-4. (Pubitemid 33739185)
12. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;22:337-45. (Pubitemid 38944402)
13. Tabernero J, Pfeiffer P, Cervantes A. Administration of cetux-imab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? The Oncologist. 2008;13:113-9. (Pubitemid 351342574)
14. Ramanathan RK. Alternative dosing schedules for cetuximab: a role for biweekly administration? Clin Colorectal Cancer. 2008; 7:364-8.
15. Czejka M, Gruenberger B, Kiss A, Farkouh A, Schueller J. Pharmacokinetics of irinotecan in combination with biweekly cetuximab in patients with advanced colorectal cancer. Antican-cer Res. 2010;30:2355-60.
16. Pfeiffer P, Nielsen D, Yilmaz M, Iversen A, Vejlø C, Jensen BV, et al. Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxa-liplatin and 5-fluorouracil. Acta Oncol. 2007;46:697-701. (Pubitemid 46911904)
17. Pfeiffer P, Nielsen D, Bjerregaard J, Qvortrup C, Yilmaz M, Jensen B, et al. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol. 2008; 19:1141-5. (Pubitemid 351796340)
18. Catalogue of somatic mutations in cancer [Internet] [updated 2010 March 8; cited 2010 march 9]. http://www.sanger.ac.uk/genetics/CGP/cosmic/.
19. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophagus-gastric cancer-pooled analysis from three multicentre randomized controlled trials using individual patient data. J Clin Oncol. 2004;22:2395-403. (Pubitemid 41121931)
20. Wilson D, Hillert L, Geh Ji, et al. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol. 2005;17:81-91.
21. Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC, et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol. 2007;18:886-91. (Pubitemid 47054086)
22. Sym SJ, Chang HM, Kang HJ, Lee SS, Ryu MH, Lee JL, et al. A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer. Cancer Chemother Pharmacol. 2008;63:1-8.
23. Kim DY, Kim JH, Lee SH, Kim TY, Heo DS, Bang YJ, et al. Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol. 2003;14:383-7. (Pubitemid 36367414)
24. Catalano V, Graziano F, Santini D, D'Emidio S, Baldelli AM, Rossi D, et al. Second-line chemotherapy for patients with gastric cancer: who may benefit? Br J Cancer. 2008;99:1402-7.
25. Moon TW, Rha SY, Jeung H, Kim C, Hong MH, Chang H, et al. Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. Cancer Chemother Pharmacol. 2010;66:797-805.
26. Hashimoto K, Takashima A, Nagashima K, Okazaki S, Nakajima TE, Kato K, et al. Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer. J Cancer Res Clin Oncol. 2010;136:1059-64.
27. Kanagaval D, Pokataev IA, Fedyanin MY, Tryakin AA, Bazin IS, Narimanov MN, et al. A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol. 2010;21:1779-85.
28. Becker JC, Muller-Tidow C, Serve H, Domschke W, Pohle T. Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J Gastroenterol. 2006;12:3297-305. (Pubitemid 43933772)
29. Patel D, Bassi R, Hooper A, Prewett M, Hicklin DJ, Kang X, et al. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. Int J Oncol. 2009;34:25-32.
30. Shimura T, Kataoka H, Ogasawara N, Kubota E, Sasaki M, Tanida S. Suppression of proHB-EGF carboxy-terminal fragment nuclear translocation: a new molecular target therapy for gastric cancer. Clin Cancer Res. 2008;14:3956-65.
31. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-65.
32. Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastro esophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol. 2007;18:110-7.
33. Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008;19:1450-7.
34. Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bükki J, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol. 2004;15:1773-81. (Pubitemid 40017161)
35. Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Wöll E, et al. Cetuximab plus oxaliplatin/leukovorin/5-fluor-ouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internististische Onkologie (AIO). Br J Cancer. 2010;102:500-5.
36. Pinto C, Di Fabio F, Siena S, Falcone A, Cascinu S, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-esophageal junction adenocarcinoma (DOCETUX study). Br J Cancer. 2009;101:1261-8.
37. Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer. 2009;100:298-304.
38. Stein A, Al-Batran SE, Arnold D, Peinert S, Siewczynski R, Schmoll HJ. Cetuximab with irinotecan as salvage therapy in heavily pretreated patients with metastatic gastric cancer J Clin Oncol. 2007 (abstract 47).
39. Park SR, Kook M, Choi IJ, Kim CH, Lee JY, Cho SJ, et al. Predictive factors for efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients. Cancer Chemother Pharmacol. 2010;65:579-87.
40. Gold J, Goldman B, Iqbal S, Leichman LP, Zhang W, Lenz HJ, et al. Cetuximab as second-line therapy in patients with meta-static esophageal adenocarcinoma. J Thorac Oncol. 2010; 5:1472-6.